Lupin's subsidiary, Lupin Inc., has acquired Symbiomix Therapeutics LLC. Lupin had entered into an option to acquire the company earlier this year. Symbiomix is a privately held company focused on bringing innovative therapies to the market for gynecologic infections that can have serious health consequences. The acquisition has been made for a cash consideration of 1005 crore (USD 150 million) including 335 crore (USD 50 million) upfront and other time-based payments. In addition, there are sales-based contingent payments. The acquisition is funded from internal funds.

The acquisition of Symbiomix and the Solosec franchise significantly expands Lupin's branded women's health specialty business, which is presently anchored by Methergine (Methylergonovine) tablets.

On September 15, 2017, the United States Food and Drug Administration (US FDA) approved Symbiomix's lead product, Solosec (Secnidazole) oral granules, for the treatment of bacterial vaginosis (BV) in adult women. Lupin expects Solosec to be commercially available by mid-2018. Solosec is the first and only single-dose oral treatment approved for BV, the most prevalent gynecologic infection in the United States, affecting 21 million women aged 14–49 annually.

10 Diagnostic Imaging Trends for 2018



Digital version